SEARCH

SEARCH BY CITATION

References

  • 1
    Hirsch H, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S21S.
  • 2
    Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001; 119: 22S38S.
  • 3
    Weibert RT, Palinkas LA. Differences in warfarin dose requirements between Asian and Caucasian patients. Clin Pharmacol 1991; 49: 151.
  • 4
    Yu HCM, Chan TYK, Critchely JAJH, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996; 89: 12735.
  • 5
    Chenhsu RY, Chiang SC, Chou MH, Lin MF. Long-term treatment with warfarin in Chinese population. Ann Pharmacotherapy 2000; 34: 1395401.
  • 6
    You JHS, Chan FWH, Wong RSM, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 5827.
  • 7
    Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 228593.
  • 8
    Veenstra DL, You JHS, Rieder MJ, Farin FM, Wilkerson H, Blough DK, Cheng G, Rettie AE. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenetics Genomics 2005; 15: 68791.
  • 9
    Yuan HY, Chen JJ, Lee MTM, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Mol Genet 2005; 14: 174551.
  • 10
    Ellis RF, Stephens MA, Sharp GB. Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm 1992; 49: 38794.
  • 11
    Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patients self-monitoring, and patient self-management. Am Heart J 1996; 132: 1095100.
  • 12
    Foss MT, Schoch PH, Sintek CD. Efficient operation of a high-volume anticoagulation clinic. Am J Health-Syst Pharm 1999; 56: 4439.
  • 13
    Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995; 15: 7329.
  • 14
    Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR. Comparing the quality of oral anticoagulation management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169: 2938.
  • 15
    Havrda DE, Hawk TL, Marvin CM. Accuracy and precision of the CoaguChek S versus laboratory INRs in a clinic. Ann Pharmacother 2002; 36: 76975.
  • 16
    Rosendaal FR, Cannegieter SC, Van Der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 2369.
  • 17
    Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 16417.
  • 18
    Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinc. Am J Hosp Pharm 1985; 42: 3048.
  • 19
    Fihn SD, McDonell M, Martin D. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 51120.
  • 20
    Conte RR, Kehoe WA, Nielson N, Lodhia H. Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm 1986; 43: 24604.
  • 21
    Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 317.
  • 22
    Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69: 31620.